CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Total revenue		$ 14,969	$ 802
Operating expenses
Research and development		42,236	44,874
General and administrative		29,670	39,842
Goodwill impairment		12,209	0
Total operating expenses		84,115	84,716
Other operating income		1,176	0
Loss from operations		(67,970)	(83,914)
Other income/(expense):
Interest income		2,678	2,877
Interest expense		(53)	(28)
Research and development incentives		3,983	3,461
Other income		135	1,082
Total other income, net		6,743	7,392
Loss before income tax		(61,227)	(76,522)
Tax benefit		44	3,075
Net loss		(61,183)	(73,447)
Net loss attributable to noncontrolling interest		109	100
Net loss attributable to Barinthus Biotherapeutics plc shareholders		$ (61,074)	$ (73,347)
Weighted-average ordinary shares outstanding, basic (in shares)		39,348,240	38,386,491
Weighted-average ordinary shares outstanding, diluted (in shares)		39,348,240	38,386,491
Net loss per share attributable to ordinary shareholders, basic (in usd per share)		$ (1.55)	$ (1.91)
Net loss per share attributable to ordinary shareholders, diluted (in usd per share)		$ (1.55)	$ (1.91)
Net loss		$ (61,183)	$ (73,447)
Other comprehensive (loss)/gain – foreign currency translation adjustments		(2,549)	10,151
Comprehensive loss		(63,732)	(63,296)
Comprehensive loss attributable to noncontrolling interest		105	94
Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders		(63,627)	(63,202)
License revenue
Total revenue	[1]	$ 14,969	$ 802

[1] All license revenue is from related parties and is generated in the United Kingdom for the years ended December 31, 2024 and 2023.